Skip to main content

Table 1 Patient characteristics

From: Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells

Group Women/men (% women) Age: years ± SD (range) Mean EDSS at the sampling (interval) Treatment duration (months or infusions ± SD) Previous treatment
HD (n = 23) 18/5 (78 %) 33 ± 11 (20–60) n.d. n.d. n.d.
UT (n = 19) 12/7 (63 %) 41 ± 8 (27–57) 1.3 (0–3) n.d. n.d.
GA (n = 26) 16/10 (62 %) 44 ± 11 (22–60) 1.9 (0–8.5) 45 ± 38 (1–122) 13/26 IFNb; 9/26 nv; 4/26 IS
IFNb (n = 26) 15/11 (58 %) 36 ± 11 (24–65) 1.6 (0–5) 51 ± 48 (3–147) 25/26 nv; 1/26 GA
NTZ (n = 113) 76/37 (67 %) 37 ± 9 (19–60) 2.9 (0–8) 35 ± 24 (1–86) 52/113 IFNb; 23/113 GA; 13/113 IS; 12/113 nv; 6/113 FTY; 7/113 other treatments
RTX (n = 18) 15/3 (83 %) 41 ± 10 (30–65) 4.4 (2–7) 1.25 (1–3) 1/18 IFNb; 1/18 GA; 5/18 FTY; 9/18 NTZ; 2/18 n.d.
FTY (n = 23) 15/8 (65 %) 41 ± 9 (21–57) 3.1 (0–6.5) 15 ± 8 (1–29) 1/23 nv; 8/23 NTZ; 5/23 GA; 5/23 IFNb; 2/23 IS; 2/23 other treatments
  1. HD healthy donors, UT untreated multiple sclerosis patients, GA glatiramer acetate, IFNb interferon-beta, NTZ natalizumab, RTX rituximab, FTY fingolimod, n.d. not determined or not applicable, EDSS Expanded Disability Status Scale, nv naïve patient, IS immunosuppressive drug